A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

Berns, Katrien, Horlings, Hugo M., Hennessy, Bryan T., Madiredjo, Mandy, Hijmans, E. Marielle, Beelen, Karin, Linn, Sabine C., Gonzalez-Angulo, Ana Maria, Stemke-Hale, Katherine, Hauptmann, Michael, Beijersbergen, Roderick L., Mills, Gordon B., van de Vijver, Marc J., Bernards, René·2007·Cancer Cell

DOI 10.1016/j.ccr.2007.08.030

Cited by (1,001)

Items 301–400 of 1,001

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial
Perez, Edith A., Dueck, Amylou C., McCullough, Ann E., Chen, Beiyun, Geiger, Xochiquetzal J., Jenkins, Robert B., Lingle, Wilma L., Davidson, Nancy E., Martino, Silvana, Kaufman, Peter A. et al. · 2013 · Journal of Clinical Oncology
Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer
Howard A. Burris, Jay Tibbitts, Scott N. Holden, Mark X. Sliwkowski, Gail D. Lewis Phillips · 2011 · Clinical Breast Cancer
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
Clifford A. Hudis, Charles Swanton, Yelena Yuriy Janjigian, Ray Lee, Stephanie Sutherland, Robert James Lehman, Sarat Chandarlapaty, Nicola Hamilton, Devika Gajria, James Knowles et al. · 2013 · Breast Cancer Research
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study
Filippo Pietrantonio, Giovanni Fucà, Federica Morano, Annunziata Gloghini, Simona Corso, Giuseppe Aprile, Federica Perrone, Ferdinando De Vita, Elena Tamborini, Gianluca Tomasello et al. · 2017 · Clinical Cancer Research
Self-Assembly of Lithographically Patterned Nanoparticles
Jeong‐Hyun Cho, David H. Gracias · 2009 · Nano Letters
HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
Jasmeet Chadha Singh, Komal L. Jhaveri, Francisco J. Esteva · 2014 · British Journal of Cancer
Use of molecular markers for predicting therapy response in cancer patients
Michael Joe Duffy, Norma O’Donovan, John Paul Crown · 2010 · Cancer Treatment Reviews
A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments
Kenta Masui, Beatrice Gini, J. Wykosky, Ciro Zanca, Paul S. Mischel, Frank B. Furnari, Webster K. Cavenee · 2013 · Carcinogenesis
Our changing view of the genomic landscape of cancer
Daphne W. Bell · 2009 · The Journal of Pathology
Trastuzumab Emtansine: A Novel Antibody–Drug Conjugate for HER2-Positive Breast Cancer
Ian E. Krop, Eric P. Winer · 2013 · Clinical Cancer Research
The prognostic value of PI3K mutational status in breast cancer: A meta‐analysis
Navid Sobhani, Giandomenico Roviello, Silvia Paola Corona, Maurizio Scaltriti, Anna Ianza, Marina Bortul, Fabrizio Zanconati, Daniele Generali · 2018 · Journal of Cellular Biochemistry
Should individual PI3 kinase isoforms be targeted in cancer?
Shidong Jia, Thomas M. Roberts, Jean J. Zhao · 2009 · Current Opinion in Cell Biology
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
Sérgio Rizzo, Giuseppe Bronte, Daniele Fanale, Lidia Rita Corsini, Nicola Silvestris, Daniele Santini, Gaspare Gulotta, Viviana Bazan, Nicola Gebbia, Fabio Fulfaro et al. · 2010 · Cancer Treatment Reviews
Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells
Giuliana Cassinelli, Valentina Zuco, Laura Gatti, Cinzia Lanzi, Nadia Zaffaroni, Diego Colombo, Paola Perego · 2013 · Current Medicinal Chemistry
The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress
Afsane Bahrami, Majid Khazaei, Soodabeh Shahidsales, Seyed Mahdi Hassanian, Malihe Hasanzadeh, Mina Maftouh, Gordon A. Ferns, Amir Avan · 2017 · Journal of Cellular Biochemistry
Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop
Zhengyan Yang, Liang Guo, Dan Liu, Limin Sun, Hongyu Chen, Que Deng, Yanjun Liu, Ming Yu, Yuan-fang Ma A, Ning Guo et al. · 2014 · Oncotarget
HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes
Lisa Vermij, Nanda Horeweg, Alicia León‐Castillo, Tessa A. Rutten, Linda Mileshkin, Helen J MacKay, Alexandra F. Leary, Melanie E. B. Powell, Naveena Singh, Emma Jayne Crosbie et al. · 2020 · Cancers
Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
Mariana K. Najjar, Sara G. Manore, Angelina T. Regua, Hui‐Wen Lo · 2022 · Genes
Trastuzumab deruxtecan in breast cancer
Martín, Miguel, Pandiella, Atanasio, Vargas-Castrillón, Emilio, Díaz-Rodríguez, Elena, Iglesias-Hernangómez, Teresa, Martínez Cano, Concha, Fernández-Cuesta, Inés, Winkow, Elena, Perelló, Maria Francesca · 2024 · Critical Reviews in Oncology/Hematology
Taming the dragon: genomic biomarkers to individualize the treatment of cancer
Ian J. Majewski, René Bernards · 2011 · Nature Medicine
mTOR as a therapeutic target in patients with gastric cancer
Salah Eddin Al-Batran, Michel Pierre Ducreux, Atsushi Ohtsu · 2011 · International Journal of Cancer
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
Dwan‐Ying Chang, Weili Ma, Yen‐Shen Lu · 2021 · Therapeutics and Clinical Risk Management
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3
Chakrabarty, A, Rexer, B N, Wang, S E, Cook, R S, Engelman, J A, Arteaga, C L · 2010 · Oncogene
Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma
Zengjin Liu, Huamin Han, Xin He, Shouwei Li, Chenxing Wu, Chunjiang Yu, Shengdian Wang · 2016 · Oncology Letters
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T‐DM1) vs. treatment of physician's choice in previously treated HER2‐positive advanced breast cancer
Sung‐Bae Kim, Hans P. M. W. Wildiers, Ian E. Krop, Melanie C. Smitt, Ron Yu, Sanne Lysbet de Haas, Antonio González-Martı́n · 2016 · International Journal of Cancer
Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
Joan T. Garrett, Cammie R. Sutton, María Gabriela Kuba, Rebecca S. Cook, Carlos L. Arteaga · 2012 · Clinical Cancer Research
Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
Dorte Lisbet Nielsen, Iben Kümler, Jesper Andreas Palshof, Michael Andersson · 2012 · The Breast
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
Ana Maria Gonzalez-Angulo, George R. Blumenschein · 2012 · Cancer Treatment Reviews
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
Mothaffar Fahed Rimawi, Carmine De Angelis, Alejandro Contreras, Fresia G. Pareja, Felipe Correa Geyer, Kathleen A. Burke, Sabrina Herrera, Tao Wang, Ingrid A. Mayer, Andres Forero et al. · 2017 · Breast Cancer Research and Treatment
HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care
Alessandra Fabi, Anna Di Benedetto, Giulio Metro, Letizia Perracchio, Cecilia Nisticò, Franco Di Filippo, Cristiana Ercolani, Gianluigi Ferretti, Elisa Melucci, Simonetta Buglioni et al. · 2011 · Clinical Cancer Research
Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction
Andrea Bertotti, Mike F. Burbridge, Stefania Gastaldi, Francesco Galimi, Davide Torti, Enzo Médico, Silvia Giordano, Simona Corso, Gaëlle Rolland-Valognes, Brian Paul Lockhart et al. · 2009 · Science Signaling
The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations
Hiroshi Tanaka, Miyuki Yoshida, Hiromi Tanimura, Toshihiko Fujii, Kiyoaki Sakata, Yukako Tachibana, Jun Ohwada, Hirosato Ebiike, Shino Kuramoto, Keiichi Morita et al. · 2011 · Clinical Cancer Research
The Nuclear Receptor Coactivator Amplified in Breast Cancer-1 Is Required for Neu (ErbB2/HER2) Activation, Signaling, and Mammary Tumorigenesis in Mice
Mark Fereshteh, Maddalena T. Tilli, Sung Eun Kim, Jianming Xu, Bert W. O’Malley, Anton Wellstein, Priscilla A. Furth, Anna Tate Riegel · 2008 · Cancer Research
Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway
Rita Nahta, Ruth M O'Regan · 2010 · Clinical Breast Cancer
β2-AR signaling controls trastuzumab resistance-dependent pathway
Daifang Liu, Zhengyan Yang, Tianxun Wang, Zhengyan Yang, H Chen, Yi Hu, C Hu, Liang Guo, Qinqin Deng, Y Liu et al. · 2015 · Oncogene
The Emerging Genomic Landscape of Endometrial Cancer
Matthieu Le Gallo, Daphne W. Bell · 2013 · Clinical Chemistry
p85 Associates with Unphosphorylated PTEN and the PTEN-Associated Complex
Rosalia Rabinovsky, Panisa Pochanard, Chontelle J. McNear, Saskia M. Brachmann, Jonathan S. Duke‐Cohan, Levi A. Garraway, William R. Sellers · 2009 · Molecular and Cellular Biology
Antibody‐Incorporated Nanomedicines for Cancer Therapy
Shun‐Yu Wu, Fu‐Gen Wu, Xiaoyuan Shawn Chen · 2022 · Advanced Materials
Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway
Sharon T. Wilks · 2015 · The Breast
The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells
Kristine Kleivi Sahlberg, Vesa Hongisto, Henrik Edgren, Rami Mäkelä, Kirsi Hellström, Eldri Undlien Due, Hans Kristian Moen Vollan, Niko Sahlberg, Maija Wolf, Anne‐Lise Børresen‐Dale et al. · 2012 · Molecular Oncology
Dysregulation of the Phosphatidylinositol 3-Kinase Pathway in Thyroid Neoplasia
John E. Paes, Matthew David Ringel · 2008 · Endocrinology and Metabolism Clinics of North America
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
Alison Elizabeth Smith, Emanuela Ferraro, Anton Mikhailovich Safonov, Cristina Bernadó Morales, Enrique Javier Arenas, Qing Li, Amanda R. Kulick, Dara S. Ross, David B. Solit, Elisa de Stanchina et al. · 2021 · Nature Communications
Her2 cross talk and therapeutic resistance in breast cancer
Laura, M. Bender · 2008 · Frontiers in bioscience
Cell-Autonomous and Non–Cell-Autonomous Mechanisms of HGF/MET–Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective
Simona Corso, Silvia Giordano · 2013 · Cancer Discovery
Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution
Subramanian Venkatesan, Charles Swanton, Barry S. Taylor, J Costello · 2017 · Cold Spring Harbor Perspectives in Medicine
ERBB2 -Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies
Jody C. Chuang, Henning Stehr, Ying Liang, Millie Snigdha Das, Jane Q. Huang, Maximilian Diehn, Heather A. Wakelee, Joel W. Neal · 2017 · Journal of Thoracic Oncology
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
M Cizkova, M.E. Dujaric, Jacqueline Lehmann‐Che, Véronique Scott, Olivier Tembo, Bernard Jean Roger Asselain, Jean‐Yves Pierga, Michel E. Marty, Patricia de Crémoux, F. Spyratos et al. · 2013 · British Journal of Cancer
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
Mohd Syahizul Nuhairy Mohd Sharial, John Paul Crown, Bryan T. Hennessy · 2012 · Annals of Oncology
Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
Roger Y. Tsang, Richard S. Finn · 2012 · British Journal of Cancer
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
Qiao Li, Xiuwen Guan, Shanshan Chen, Zongbi Yi, Bo Lan, Puyuan Xing, Ying Fan, Jiayu Wang, Yang Luo, Peng Yuan et al. · 2019 · Clinical Cancer Research
Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers
Joan T. Garrett, Cammie R. Sutton, Richard Kurupi, Carl Uli Bialucha, Seth A. Ettenberg, Scott D. Collins, Qing Sheng, Jerry Wallweber, Lisa D. Eli, Carlos L. Arteaga · 2013 · Cancer Research
Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
Xueda Hu, Zemin Zhang · 2015 · Trends in Genetics
β1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2–Positive Breast Cancer
David M. Lesniak, Yaoxian Xu, Jean Deschênes, Raymond L. Lai, John Thoms, David Murray, Sunita Gosh, John Robert Mackey, Siham Sabri, Bassam Abdulkarim · 2009 · Cancer Research
Towards systematic functional characterization of cancer genomes
Jesse S. Boehm, William C. Hahn · 2011 · Nature Reviews Genetics
The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition
Jiaolong Shi, Fengping Li, Xingxing Yao, Tingyu Mou, Zhijun Xu, Zheng Han, Siyu Chen, Wende Li, Jiang Yu, Xiaolong Qi et al. · 2018 · Oncogene
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
Rita Nahta · 2012 · ISRN Oncology
Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling
Thomas W. Grunt, Gabriella Lucia Mariani · 2013 · Current Cancer Drug Targets
HER2 as a target for breast cancer therapy
Elda Tagliabue, Andrea Balsari, Manuela Campiglio, Serenella Maria Pupa · 2010 · Expert Opinion on Biological Therapy
Actionable gene-based classification toward precision medicine in gastric cancer
Hiroshi Ichikawa, Masayuki Nagahashi, Yoshifumi Shimada, Takaaki Hanyu, Takashi Ishikawa, Hitoshi Kameyama, Takashi Kobayashi, Jun Sakata, Hiroshi Yabusaki, Satoru Nakagawa et al. · 2017 · Genome Medicine
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility
Loredana Vecchione, Valentina Gambino, Jonne A. Raaijmakers, Andreas Schlicker, Arianna Fumagalli, Mariangela Russo, Alberto Villanueva, Evelyne Beerling, Alice Bartolini, David G. Mollevı́ et al. · 2016 · Cell
Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer
Yinnan Chen, Yanmin Zhang · 2018 · Advanced Science
Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
Elena Dı́az-Rodrı́guez, Lucía Gandullo‐Sánchez, Alberto Ocaña, Atanasio Pandiella · 2021 · Cancers
Optical imaging of metabolism in HER2 overexpressing breast cancer cells
Alex J. Walsh, Rebecca S. Cook, Brent Neil Rexer, Carlos L. Arteaga, Melissa C. Skala · 2011 · Biomedical Optics Express
HER2-family signalling mechanisms, clinical implications and targeting in breast cancer
Naomi Elster, Denis Martin Collins, Sinéad Toomey, John Paul Crown, Alex J. Eustace, Bryan T. Hennessy · 2014 · Breast Cancer Research and Treatment
Anti-HER agents in gastric cancer: from bench to bedside
Lorenzo Fornaro, M Lucchesi, Chiara Caparello, Enrico Vasile, S. Caponi, Laura Ginocchi, Gianluca Masi, Alfredo Falcone · 2011 · Nature Reviews Gastroenterology & Hepatology
Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer
Yasutaka Sukawa · 2012 · World Journal of Gastroenterology
Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Ondrej Kalous, Dylan F. Conklin, Amrita J. Desai, Neil A. O’Brien, Charles Ginther, Lee A. Anderson, David J. Cohen, Carolyn D. Britten, Ian W. Taylor, James G. Christensen et al. · 2012 · Molecular Cancer Therapeutics
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients
Sylvain Lefort, Aurélie Thuleau, Yann Kieffer, Philémon Sirven, Ivan Bièche, Elisabetta Marangoni, Anne Vincent‐Salomon, Fatima Mechta‐Grigoriou · 2016 · Oncogene
HER2 Expression and PI3K-Akt Pathway Alterations in Gastric Cancer
Yasutaka Sukawa, Hiroyuki Yamamoto, Katsuhiko Nosho, Miki Ito, Hisayoshi Igarashi, Takafumi Naito, Kei Mitsuhashi, Yasutaka Matsunaga, Taiga Takahashi, Masashi Mikami et al. · 2014 · Digestion
Differential Enhancement of Breast Cancer Cell Motility and Metastasis by Helical and Kinase Domain Mutations of Class IA Phosphoinositide 3-Kinase
Huan Pang, Rory J. Flinn, Antonia Patsialou, Jeffrey B. Wyckoff, Evanthia T. Roussos Torres, Haiyan Wu, Maria Pozzuto, Sumanta Kumar Goswami, John S. Condeelis, Anne R. Bresnick et al. · 2009 · Cancer Research
Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer
Liyun Luo, Zhijie Zhang, Ni Qiu, Li Ling, Xiaoting Jia, Ying Song, Hongsheng Li, Jiansheng Li, Hui Lyu, Hao Liu et al. · 2021 · Nature Communications
Everolimus in the Treatment of Metastatic Breast Cancer
Melanie Royce, Diaa I. Osman · 2015 · Breast Cancer Basic and Clinical Research
Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists
Brent Neil Rexer, Jeffrey A. Engelman, Carlos L. Arteaga · 2009 · Cell Cycle
Selective Inhibition of HER2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir
Joong Sup Shim, Rajini Rao, Kristin E. Beebe, Len Neckers, Inkyu Han, Rita Nahta, Jun O. Liu · 2012 · JNCI Journal of the National Cancer Institute
The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer
Elisabeth Diver, Rosemary Foster, Bo R. Rueda, Whitfield B. Growdon · 2015 · The Oncologist
HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer
Tetsushi Kubota, Shinji Kuroda, Nobuhiko Kanaya, Toshiaki Morihiro, Katsuyuki Aoyama, Yoshihiko Kakiuchi, Satoru Kikuchi, Masahiko Nishizaki, Shunsuke Kagawa, Hiroshi Tazawa et al. · 2018 · Nanomedicine Nanotechnology Biology and Medicine
An RNA Interference Screen Identifies Metabolic Regulators NR1D1 and PBP as Novel Survival Factors for Breast Cancer Cells with the ERBB2 Signature
Antonis Kourtidis, Ritu Jain, Richard D. Carkner, Cheryl Eifert, M. Julia Brosnan, Douglas S. Conklin · 2010 · Cancer Research
Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients
Helen Schneck, Christina Blassl, Franziska Meier-Stiegen, Rui P. Neves, Wolfgang Janni, Tanja Natascha Fehm, Hans J. Neubauer · 2013 · Molecular Oncology
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells
Brent Neil Rexer, Siprachanh Chanthaphaychith, Kimberly Brown Dahlman, Carlos L. Arteaga · 2014 · Breast Cancer Research
An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients
Geny Piro, Carmine Carbone, Ivana Cataldo, Federica Di Nicolantonio, Simone Giacopuzzi, Giuseppe Aprile, Francesca Simionato, Federico Boschi, Marco Zanotto, Maria Mihaela Mina et al. · 2016 · Clinical Cancer Research
The Role of Cancer Stem Cells in Breast Cancer Initiation and Progression: Potential Cancer Stem Cell-Directed Therapies
Panagiota Economopoulou, Virginia Kaklamani, Kalliopi P. Siziopikou · 2012 · The Oncologist
Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference
Daniel S.W. Tan, Marco Gerlinger, Bin Tean Teh, Charles Swanton · 2010 · European Journal of Cancer
Advances in the Management of HER2-positive Advanced Gastric and Gastroesophageal Junction Cancer
Yung‐Jue Bang · 2012 · Journal of Clinical Gastroenterology
HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
Mari K. Halle, Ingvild Løberg Tangen, Hege Fredriksen Berg, Erling André Høivik, Karen Klepsland Mauland, Kanthida Kusonmano, Anna Berg, Antoni Hurtado, Karl‐Henning Kalland, Anne Margrete Oyan et al. · 2017 · British Journal of Cancer
Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
Andrea Li‐Ann Wong, Soo Chin Lee · 2012 · International Journal of Breast Cancer
Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression
Guangchao Li, Likun Zhao, Wěi Li, Kexing Fan, Weizhu Qian, Sheng Hou, Hao Wang, Jianxin Dai, Huafeng Wei, Yajun Guo · 2014 · Oncotarget
Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
Yibing Yan, Violeta Serra, Ludmila Prudkin, Maurizio Scaltriti, Sumati Murli, Olga Rodríguez, Marta Guzmán, Deepak Sampath, Michelle Nannini, Yuanyuan Xiao et al. · 2013 · Clinical Cancer Research
Insulin Receptor Substrate Regulation of Phosphoinositide 3-Kinase
Heather E. Metz, A. McGarry Houghton · 2010 · Clinical Cancer Research
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2–Altered Advanced Solid Tumors
Christopher J. Sweeney, John Daniel Hainsworth, Ron Bose, Howard A. Burris, Razelle Kurzrock, Charles Swanton, Claire Frances Friedman, David Robert Spigel, Tania Szado, Katja Schulze et al. · 2023 · Journal of Clinical Oncology
Ethics of Mandatory Research Biopsy for Correlative End Points Within Clinical Trials in Oncology
Jeffrey M. Peppercorn, Iuliana Shapira, Deborah E. Collyar, Teresa L. Deshields, NU Lin, Ian E. Krop, HANS W. GRUNWALD, Paula N. Friedman, Ann H. Partridge, Richard L. Schilsky et al. · 2010 · Journal of Clinical Oncology
Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2+ Metastatic Breast Cancer
Hilda Wong, Roland Ching-Yu Leung, Ava Kwong, Joanne Wing Yan Chiu, Raymond Hin-Suen Liang, Charles Swanton, Thomas C. C. Yau · 2011 · The Oncologist
The PTEN tumor suppressor gene and its role in lymphoma pathogenesis
Xiaoxiao Wang, Huiqiang Huang, Ken H. Young · 2015 · Aging
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
Wenhao Shi, Tingting Jiang, Paolo Giovanni Nuciforo, Christos Hatzis, Eileen McCormick Holmes, Nadia Harbeck, Christos Sotiriou, L. Peña, Sherene Loi, Daniela D. Rosa et al. · 2016 · Annals of Oncology
HER2-positive breast cancer is lost in translation: time for patient-centered research
Isabelle Gingras, Géraldine Gebhart, Evandro de Azambuja, Martine J Piccart · 2017 · Nature Reviews Clinical Oncology
Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
Bowen Sun, Seth Mason, Robert C. Wilson, E. Starr Hazard, Yubao Wang, Rong Fang, Qiwei Wang, Elizabeth Shinmay Yeh, Meixiang Yang, Thomas M. Roberts et al. · 2019 · Oncogene
PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis
Babette Schade, Trisha Rao, Nathalie Dourdin, Robert Lesurf, Michael T. Hallett, Robert D. Cardiff, William J. Muller · 2009 · Journal of Biological Chemistry
Optimal targeting of the mTORC1 kinase in human cancer
Heidi A. Lane, Madlaina Breuleux · 2009 · Current Opinion in Cell Biology
Curcumin and cancer stem cells: curcumin has asymmetrical effects on cancer and normal stem cells.
Peter P. Sordillo, Lawrence Helson · 2015 · PubMed
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment
Sílvia Cufí, Alejandro Vázquez‐Martín, Cristina Oliveras‐Ferraros, Bruna Corominas-Faja, Ander Urruticoechea, Begoña Martı́n-Castillo, Javier Abel Menéndez · 2012 · Oncotarget
Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer
Jasper Mullenders, René Bernards · 2009 · Oncogene